P. Meza-junco J. Angulo
#134,736
Most Influential Person Now
P. Meza-junco J. Angulo's AcademicInfluence.com Rankings
P. Meza-junco J. Angulophilosophy Degrees
Philosophy
#6738
World Rank
#9829
Historical Rank
Logic
#3858
World Rank
#5078
Historical Rank

Download Badge
Philosophy
P. Meza-junco J. Angulo's Degrees
- PhD Biomedical Sciences University of California, San Francisco
- Doctorate Medicine Stanford University
Why Is P. Meza-junco J. Angulo Influential?
(Suggest an Edit or Addition)P. Meza-junco J. Angulo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The natural history of nonalcoholic fatty liver disease: a population-based cohort study. (2005) (2733)
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) (2381)
- Nonalcoholic fatty liver disease. (2002) (2147)
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. (2015) (1958)
- Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis (1999) (1618)
- Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. (2003) (959)
- The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. (2005) (904)
- Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (2004) (698)
- Nonalcoholic fatty liver disease (2005) (652)
- The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years (2009) (647)
- Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. (2015) (556)
- Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis (2004) (474)
- Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study (2001) (417)
- Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. (2013) (417)
- The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study (2011) (403)
- GI Epidemiology: nonalcoholic fatty liver disease (2007) (390)
- Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial (2008) (378)
- NAFLD in children: A prospective clinical‐pathological study and effect of lifestyle advice (2006) (339)
- Recent concepts in non‐alcoholic fatty liver disease (2005) (337)
- Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. (2005) (328)
- Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis (2015) (315)
- Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study (2008) (312)
- The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis (2005) (301)
- Obesity and nonalcoholic fatty liver disease. (2007) (268)
- Noninvasive evaluation of NAFLD (2013) (262)
- The natural history of small-duct primary sclerosing cholangitis. (2008) (255)
- Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study (2010) (253)
- A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis (2004) (246)
- Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction (2004) (225)
- Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease (2005) (216)
- High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis (2000) (211)
- Long‐term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? (2010) (211)
- Primary sclerosing cholangitis in children: A long‐term follow‐up study (2003) (210)
- Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis (2000) (209)
- Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial (2009) (206)
- Chronological development of elevated aminotransferases in a nonalcoholic population (2005) (204)
- Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study (2009) (199)
- Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. (2004) (197)
- The Prevalence of Autoantibodies and Autoimmune Hepatitis in Patients with Nonalcoholic Fatty Liver Disease (2004) (195)
- Treatment of non-alcoholic fatty liver disease (2006) (195)
- Small‐duct primary sclerosing cholangitis: A long‐term follow‐up study (2002) (191)
- Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. (2000) (190)
- Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. (1999) (179)
- Is there a role for liver biopsy in primary sclerosing cholangitis? (2003) (166)
- Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. (2001) (161)
- Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. (2011) (155)
- Nutritional and Metabolic Considerations in the Etiology of Nonalcoholic Steatohepatitis (2001) (155)
- Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. (2000) (155)
- The Framingham risk score and heart disease in nonalcoholic fatty liver disease (2012) (151)
- Nonalcoholic fatty liver disease and liver transplantation (2006) (144)
- PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. (2010) (141)
- Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo‐controlled trial (2005) (141)
- Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes (2007) (136)
- Serum autoantibodies in patients with primary sclerosing cholangitis. (2000) (134)
- Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis (1999) (133)
- Treatment of nonalcoholic fatty liver: present and emerging therapies. (2001) (132)
- Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. (1999) (127)
- Tumor necrosis factor‐α and transforming growth factor‐β reflect severity of liver damage in primary biliary cirrhosis (2002) (125)
- Abnormal Hepatic Biochemistries in Patients With Inflammatory Bowel Disease (2007) (118)
- Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease (2007) (113)
- Fat-soluble vitamin levels in patients with primary biliary cirrhosis (2000) (110)
- NAFLD, obesity, and bariatric surgery. (2006) (105)
- Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? (2002) (104)
- Utility of a new model to diagnose an alcohol basis for steatohepatitis. (2006) (103)
- Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. (1998) (102)
- Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis (2004) (99)
- Secondary Sclerosing Cholangitis: A Comparison to Primary Sclerosing Cholangitis (2005) (96)
- Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2000) (96)
- Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications (2015) (95)
- 379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease (2014) (93)
- Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis. (2004) (90)
- Cost‐minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis (2004) (90)
- Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. (1999) (86)
- PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. (2012) (85)
- Bone disease in patients with primary sclerosing cholangitis. (2011) (83)
- Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. (2002) (81)
- Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. (2007) (81)
- Oral budesonide in the treatment of primary sclerosing cholangitis (2000) (78)
- Hepatitis C and steatosis. (2007) (78)
- When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? (2003) (76)
- Treatment of nonalcoholic fatty liver disease. (2002) (76)
- Primary sclerosing cholangitis (1999) (71)
- Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. (2012) (70)
- Use of ursodeoxycholic acid in patients with liver disease (2002) (70)
- The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease (2013) (70)
- Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis (2006) (70)
- Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience (2000) (69)
- Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia (2007) (69)
- Oral budesonide in the treatment of primary sclerosing cholangitis. (2000) (67)
- Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. (2001) (66)
- Nonalcoholic fatty liver disease (2005) (66)
- Can NASH be diagnosed, graded, and staged noninvasively? (2012) (65)
- Current best treatment for non-alcoholic fatty liver disease (2003) (61)
- Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. (2007) (58)
- Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study (2005) (58)
- Relations of Steatosis Type, Grade, and Zonality to Histological Features in Pediatric Nonalcoholic Fatty Liver Disease (2011) (58)
- Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. (2005) (56)
- An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. (2015) (56)
- Cholangiocarcinoma in Young Individuals With and Without Primary Sclerosing Cholangitis (2007) (55)
- Diagnosing steatohepatitis and predicting liver‐related mortality in patients with NAFLD: Two distinct concepts (2011) (52)
- Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus (2001) (51)
- Erratum: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference (Hepatology (2003) 37 (1202-1219)) (2003) (50)
- Pirfenidone in the Treatment of Primary Sclerosing Cholangitis (2004) (50)
- Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system (2002) (50)
- Oral Nicotine in Treatment of Primary Sclerosing Cholangitis (A Pilot Study) (2004) (49)
- Safety and Efficacy of Estrogen Therapy in Preventing Bone Loss in Primary Biliary Cirrhosis (2003) (48)
- Treatment of non-alcoholic steatohepatitis. (2002) (47)
- Lactulose therapy in acute liver failure (2002) (46)
- Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. (2014) (43)
- The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. (2012) (43)
- The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease (2012) (39)
- Mycophenolate Mofetil for the Treatment of Primary Biliary Cirrhosis in Patients With an Incomplete Response to Ursodeoxycholic Acid (2005) (39)
- Non‐alcoholic fatty liver disease (2002) (39)
- Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? (2001) (38)
- Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study (2008) (38)
- Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy (2003) (37)
- Time course of histological progression in primary sclerosing cholangitis (1999) (37)
- Primary sclerosing cholangitis. (2008) (37)
- Primary biliary cirrhosis and primary sclerosing cholangitis. (1999) (37)
- Varices in Early Histological Stage Primary Biliary Cirrhosis (2011) (36)
- Results of long-term ursodiol treatment for patients with primary biliary cirrhosis (2002) (36)
- Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small‐duct primary sclerosing cholangitis (2007) (35)
- Time course of histological progression in primary sclerosing cholangitis. (1999) (35)
- Treatment With Ursodeoxycholic Acid Is Associated With Weight Gain in Patients With Primary Biliary Cirrhosis (2003) (34)
- A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis (2010) (34)
- The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis (1998) (31)
- Risk Factors for Venous Thromboembolism in Patients with Chronic Liver Disease (2013) (31)
- Mycophenolate Mofetil for the Treatment of Primary Sclerosing Cholangitis (2005) (28)
- The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis (2006) (28)
- PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. (2013) (27)
- Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities? (2014) (27)
- Association of Primary Biliary Cirrhosis and Rheumatoid Arthritis (2003) (22)
- Open‐label pilot study of folic acid in patients with nonalcoholic steatohepatitis (2007) (21)
- Noninvasive assessment of fibrosis and steatosis in NASH and ASH. (2009) (20)
- Cholangiocarcinoma in pregnancy: A case report (2008) (17)
- The Natural History of NAFLD (2013) (16)
- Cetirizine-induced cholestasis (2000) (15)
- Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid (2010) (12)
- Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis (2001) (12)
- Corrections: Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? (2010) (11)
- Small-duct primary sclerosing cholangitis: Prevalence and natural history (2000) (10)
- Management of primary biliary cirrhosis and autoimmune cholangitis. (1998) (10)
- Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers? (2004) (10)
- Betaine for the treatment of nonalcoholic steatohepatitis: A promising new agent (2000) (9)
- Medical treatment for primary sclerosing cholangitis: Risk versus benefit (2000) (9)
- Primary sclerosing cholangitis. (2002) (8)
- Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis. (2001) (8)
- Primary sclerosing cholangitis: emerging new promising therapies. (2000) (8)
- Nonalcoholic fatty liver disease in children: A follow-up study for up to 16 years (2003) (7)
- Oral Tolerance and Pyruvate Dehydrogenase in Patients with Primary Biliary Cirrhosis (2002) (7)
- Correction: Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial (2010) (6)
- 715 Hyaluronic acid, an accurate serum marker for advanced fibrosis among nonalcoholic steatohepatitis (2003) (6)
- Right Upper-Quadrant Pain in a Patient with Drug Abuse, Secondary Syphilis and Occult Hepatitis B Virus (2014) (6)
- Management of NASH: Current and Future Perspectives on Treatment (2007) (5)
- S1908 Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study (2008) (5)
- 104 Time course of fibrosis progression in patients with nonalcoholic fatty liver disease (2003) (5)
- The timing of liver transplantation in primary biliary cirrhosis. (2000) (5)
- Clinical trials: Trial design in NASH—realities and challenges (2011) (4)
- S1906 Lifestyle Intervention and Antioxidants in Children with Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial (2008) (4)
- Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests (2015) (3)
- Open-Label Pilot Study of Tetracycline in the Treatment of Primary Biliary Cirrhosis (2004) (3)
- [Auto-antibodies in liver disease]. (2007) (3)
- Mo1814 Fulminant Liver Failure Secondary to “Saba Appetite Control and Energy” Weight Loss Supplement (2014) (3)
- Editorial: Noninvasive Prediction of Hepatic Steatosis (2014) (3)
- Methotrexate in the treatment of primary biliary cirrhosis: the hype and the hope. (1999) (3)
- Strengthening the bones in primary biliary cirrhosis (2013) (3)
- 714 Prevalence of autoantibodies and autoimmune hepatitis in nonalcoholic fatty liver disease (2003) (3)
- Paroxysmal nocturnal hemoglobinuria presenting as acute renal failure. (1984) (2)
- Mycophenolate mofetil for patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2003) (2)
- Oral nicotine in the treatment of primary sclerosing cholangitis: A pilot study (1998) (2)
- LIVER FAILURE AND LIVER DISEASE LIVER FAILURE Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis : A Randomized Placebo-Controlled Trial (2005) (2)
- [Acquired methemoglobinaemia (author's transl)]. (1981) (2)
- Cetirizine-induce cholestasis. (2000) (2)
- A Pilot Study: No Therapeutic Effect of L-Alanine in Patients with Nonalcoholic Steatohepatitis (2010) (2)
- Insulin Resistance, Auto-antibodies, and Nonalcoholic Fatty Liver Disease Response to Letter (2005) (2)
- Silymarin in the treatment of patients with primary scierosing cholangitis (2001) (2)
- The bulge, booze, and the liver. (2005) (2)
- The spectrum of nonalcoholic fatty liver disease with normal liver enzymes (2003) (2)
- Hepatic Steatosis and Non‐Alcoholic Fatty Liver Disease (2010) (1)
- 731 Lipid profiles in nonalcoholic fatty liver disease (2003) (1)
- Mycophenolate mofetil for patients with primary sclerosing cholangitis (2003) (1)
- Long-term ursodeoxycholic acid therapy delays histologic progression in primary biliary cirrhosis (1998) (1)
- 814 Lactulose therapy in acute liver failure (2003) (1)
- Nonalcoholic fatty liver disease: what are the odds your patient will get a transplant? (2011) (1)
- The time course of histological progression in primary sclerosing cholangitis (1998) (1)
- Is there a role for liver biopsy in primary scierosing cholangitis (PSC) (2001) (1)
- Relationship of serum cytokines and severity of liver damage in patients with nonalcoholic steatohepatitis (2001) (1)
- Hormone replacement therapy is safe and effective in decreasing bone loss in postmenopausal patients with primary biliary cirrhosis (2000) (1)
- Sarcopenic obesity and myosteratosis are associated with higher mortality in patients with cirrhosis (2016) (1)
- Cryoglobulins in nonalcoholic Fatty-liver disease: what is the association? (2012) (1)
- [Cor triatriatum with interventricular communication: Doppler color ultrasonography and magnetic resonance diagnosis. Repair in the first months]. (1997) (1)
- 645 The Framingham Risk Score Accurately Predicts the Higher Risk of Coronary Heart Disease in Patients with Nonalcoholic Fatty Liver Disease (2009) (1)
- Metabolic Syndrome and Non‐alcoholic Fatty Liver Disease (2016) (1)
- Oral pirfenidone in the treatment of primary sclerosing cholangitis (2000) (1)
- The Relationship of Steatosis Grade, Zone and Type to Key Histological Features in Children with Nonalcoholic Fatty Liver Disease: 1451 (2009) (0)
- Evaluating Risks and Complications of Liver Biopsy in Children Receiving Biopsy for Diagnosis and Treatment: 435 (2013) (0)
- Silymarin for patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2000) (0)
- Serum cytokine levels in patients with primary sclerosing cholangitis: effect of treatment with ursodeoxycholic acid (2001) (0)
- Sa1047 Increased Hepatic Iron Deposition and Long-Term Prognosis of Patients With Nonalcoholic Fatty Liver Disease (2014) (0)
- Mo1001 Prognostic Relevance of Serum Ferritin in Patients With Nonalcoholic Fatty Liver Disease (2013) (0)
- 550 Immunomodulation of mediators of inflammation, fibrosis and apoptosis in primary biliary cirrhosis and primary sclerosing cholangitis (2004) (0)
- Overlap with autoimmune hepatitis in pediatric patients with primary sclerosing cholangitis (2002) (0)
- Acute Esophageal Necrosis: 95 (2013) (0)
- Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy-Reply. (2012) (0)
- [The effect of blood clotting on several fractions of the complement system (author's transl)]. (1976) (0)
- Recurrent idiopathic hepatitis: a new entity? (2003) (0)
- [Hemoblastosis and 2d hematic disease]. (1978) (0)
- Adipose Tissue and Adipokines in Health and Disease. Humana Press, Totowa, New Jersey (2007), 402 pp. $169.00, ISBN 978-1-58829-721-1. Web site for ordering: www.humanapress.com (2008) (0)
- Association of adiposity, measures of metabolic dysregulation, and elevated alanine aminotransferase in subjects with normal body mass index (2014) (0)
- Independent predictors of severe liver fibrosis in chronic hepatitis C (2001) (0)
- 717 The spectrum of nonalcoholic fatty liver disease in patients with hypothalamic and pituitary dysfunction (2003) (0)
- LIVER, PANCREAS, AND BILIARY TRACT Prevalence and Indicators of Portal Hypertension in Patients With Nonalcoholic Fatty Liver Disease (2012) (0)
- Weight gain precedes hypertransaminasemia and insulin resistance—A prospective study in healthy individuals (2003) (0)
- Cytokines reflect the severity of the damage in non-alcoholic steatohepatitis (2002) (0)
- 747 Cytokine production and bone mineral density in patients with primary biliary cirrhosis (2003) (0)
- Chapter 34. Nonalcoholic Fatty Liver Disease (2008) (0)
- Overlap of autoimmune hepatitis with the newly modified scoring system (2000) (0)
- [Hodgkin's disease. Our 9-year experience with the 1980 protocol]. (1992) (0)
- 465 Diabetes Increases the Risk of Hepatocellular Carcinoma in Non Alcoholic Steatohepatitis and Alcoholic Cirrhosis (2015) (0)
- [The inulin test as a new screening method for the diagnosis of paroxysmal nocturnal hemoglobinuria]. (1973) (0)
- Short-term ursodeoxycholic acid therapy delays stage progression in patients with primary biliary cirrhosis (2000) (0)
- [Inulin induced platelet aggregation in patients with paroxysmal nocturnal haemoglobinuria (author's transl)]. (1976) (0)
- Response to Dr. Sekhon (2002) (0)
- Prevalence of celiac disease in a north american population with primary biliary cirrhosis - is screening worthwhile? (2000) (0)
- Harnois et al.: Study of high-dose ursodeoxycholic acid [1] (multiple letters) (2002) (0)
- [A new book interpretation of red blood cell heat-sensitivity in paroxysmal nocturnal haemoglobinuria (author's transl)]. (1976) (0)
- [Cholestatic syndromes]. (2005) (0)
- [Quantitative electroimmunodiffusion assessment of factor viii-associated antigen (author's transl)]. (1975) (0)
- Nonalcoholic Fatty Liver Diseasea (2011) (0)
- [Acceleration of coagulation by activation of the alternating route of complement]. (1974) (0)
- Acknowledgment of 2008 Reviewers (2009) (0)
- Relationship of serum cytokines and severity of liver damage in patients with nonalcoholic stestohepstitis (2001) (0)
- Ursodeoxycholic acid therapy plays an immunomodulatory and anti-apoptotic role in patients with primary sclerosing cholangitis and primary biliary cirrhosis (2003) (0)
- [Physiopathology of cellular abnormality in nocturnal paroxysmal hemoglobinuria]. (1978) (0)
- Changes in Ca 19–9 over time predict development of cholangiocarcinoma in patients with primary sclerosing cholangitis (2003) (0)
- 372 Bone Disease in Patients With Primary Sclerosing Cholangitis: Prevalence, Predictors, and Rate of Progression (2010) (0)
- [Fatty liver and steatotic non-alcoholic hepatitis]. (2004) (0)
This paper list is powered by the following services: